In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy

The E1B-deleted, replication-competent ONYX-015 (dl1520) adenovirus was ori ginally described as being able to selectively kill p53-deficient cells due to a requirement of p53 inactivation for efficient viral replication. This hypothesis has become controversial because subsequent in vitro studies ha ve demonstrated that the host range specificity of ONYX-015 is independent of p53 gene status. Using a pair of isogenic cell lines that differ only in their p53 status, we demonstrate here that although ONYX-015 can replicate in both p53 wild-type and mutant cells in vitro, the virus demonstrates si gnificantly greater antitumor activity against mutant p53 tumors in vivo. M oreover, ONYX-015 viral therapy can be combined with radiation to improve t umor control beyond that of either monotherapy, The results demonstrate tha t ONYX-015 can discern in vivo between tumors having a different p53 status and that it may be an effective neoadjuvant to radiation therapy.